At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 18 enrolled
Drug / intervention
MK-8527drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-8527 in Participants With Moderate and Severe Renal Impairment
In Brief
A Phase 1 clinical trial evaluating MK-8527 for Renal Impairment. Completed, enrolled 18 participants across 1 site.
Detailed Summary
The goal of this study is to evaluate the effect of moderate and severe renal impairment (RI) on the pharmacokinetics (PK), safety, and tolerability of MK-8527. There will be no hypothesis testing in the study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Impairment
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20252026
First PostedMar 2024
Enrollment StartJun 2024
Primary CompletionJan 2025
TodayJul 2026
First PostedMar 6, 2024
Enrollment StartJun 20, 2024
Primary CompletionJan 31, 2025
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 2.3 years ago
Interventions
MK-8527drug
Oral Capsule